RNF92/TRIM11 Polyklonal Antibody, Biotin Conjugated

E3 ubiquitin-protein ligase that promotes the degradation of insoluble ubiquitinated proteins, including insoluble PAX6, poly-Gln repeat expanded HTT and poly-Ala repeat expanded ARX. Mediates PAX6 ubiquitination leading to proteasomal degradation, thereby modulating cortical neurogenesis. May also inhibit PAX6 transcriptional activity, possibly in part by preventing the binding of PAX6 to its consensus sequences. May contribute to the regulation of the intracellular level of HN (humanin) or HN-containing proteins through the proteasomal degradation pathway. Mediates MED15 ubiquitination leading to proteasomal degradation. May contribute to the innate restriction of retroviruses. Upon overexpression, reduces HIV-1 and murine leukemia virus infectivity, by suppressing viral gene expression. Antiviral activity depends on a functional E3 ubiquitin-protein ligase domain. May regulate TRIM5 turnover via the proteasome pathway, thus counteracting the TRIM5-mediated cross-species restriction of retroviral infection at early stages of the retroviral life cycle.

BIA 1; E3 ubiquitin protein ligase TRIM11; E3 ubiquitin-protein ligase TRIM11; Protein BIA1; RING finger protein 92; RNF 92; TRI11_HUMAN; Trim 11; TRIM11; Tripartite mot containing 11; tripartite mot protein 11; Tripartite mot-containing protein 11.

81559

Human, Mouse, Rat

101-200/468

RNF92/TRIM11

Biotin

KLH conjugated synthetic peptide derived from human TRIM11/RNF92

WB, IHC-P

Purified by Protein A.

1µg/µl

WB (1:300-5000), IHC-P (1:200-400)

Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C for 12 months.

81559